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httpcense.Abstract Background: Impaired pulmonary function in patients on hemodialysis may be caused
by an underlying pulmonary disease, however the effects of hemodialysis treatment and kidney
transplantation are not well understood.
Aim of the work: The aim of this study was to evaluate pulmonary function among patients with
chronic renal failure (CRF) undergoing hemodialysis and patients with kidney transplant.
Patients and methods: This study was conducted on 60 subjects. They were classiﬁed into 3 groups:
Hemodialysis group (HDG) included 20 patients with end stage renal disease (ESRD) on regular
hemodialysis for at least six months and were clinically stable. Transplant group (TG) included 20
patients who had undergone kidney transplant at least six months earlier and were also clinically sta-
ble. Control group (CG) included 20 apparently healthy subjects. All subjects underwent pulmonary
function testing; including resting spirometry included ﬂow volume loop andMaximal VoluntaryVen-
tilation (MVV), measurement of lung volumes and diffusing capacity for carbon monoxide (DLCO)
using single breath technique, Six Minute Walking Test (6MWT) and arterial blood gases (ABG).
Results: There was a signiﬁcant difference between HDG, TG and CG regarding FVC% of pre-
dicted, FEV1% of predicted, FEF 25–75% of predicted, PEFR% of predicted and MVV% of pre-
dicted. Also there was a statistically signiﬁcant difference between HDG, TG and CG regarding
RV% of predicted, TLC% of predicted and RV/TLC%. Although FVC% of predicted and
FEV1% of predicted were within the normal range in the 3 studied groups, there was a statistically2797744, +966 507378430.
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Open access under CC Bsigniﬁcant reduction in these spirometric parameters in HDGmore than that in the TG and CG, also
reduction in TG more than CG. FEF 25–75% of predicted was less than normal in HDG and was
within the normal range in TG and CG, also RV% of predicted and TLC% of predicted were
increased inHDGmore than that in TG andCG.RegardingDLco%of predicted we found signiﬁcant
differences between the 3 studied groups. It was lower in HDG than in TG and CG. Also the same
results we found regarding Dlco/VA% of predicted. There were statistically signiﬁcant differences
among the studied groups regarding 6MWT. Regarding ABG although all values were within normal
levels, Pao2 in HDG was less than that in TG and CG.
Conclusion: There is impairment of lung function in patients with CRF undergoing hemodialysis.
The main changes are small airway obstruction, reduction in carbon monoxide transfer and dimin-
ished 6MWT that were not completely improved in the kidney transplant patients.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Chronic renal diseases are associated with a variety of respira-
tory manifestations. Pulmonary edema, pleural disease, pul-
monary calciﬁcation, and sleep apnea syndrome have been
documented in patients with chronic renal failure. Further-
more, treatment with hemodialysis also produces transient
changes in pulmonary gas exchange [1]. Impaired pulmonary
function in patients on hemodialysis may be caused by an
underlying pulmonary disease, however, the impact of uremia
and the effects of hemodialysis treatment are not well under-
stood. Several mechanisms may impair pulmonary function
and alter bronchial responsiveness in patients on long term
regular hemodialysis treatment, some of which are trapping
of neutrophils, increased extra-vascular lung water, left ven-
tricular hypertrophy, metastatic lung calciﬁcation, and iron
deposition [2,3]. On the other hand, hemodialysis can result
in better respiratory function [4]. The muscles responsible for
respiratory function, such as the diaphragm and intercostals,
among others, are classiﬁed as skeletal muscles and may show
decreases in muscle strength and endurance properties result-
ing from uremic myopathy. Some authors [5] who have studied
the involvement of uremia in the diaphragm have concluded
that loss of strength occurs through severe uremia. The venti-
latory deﬁcit due to this impairment in respiratory muscles,
combined with other lung tissue impairments, compromises
the functioning of this system, thereby contributing toward de-
creased lung capacity [6,7]. During hemodialysis, the majority
of patients develop a reduction in arterial PO2. The arterial
PO2 falls within a few minutes of initiation of dialysis by 10–
15 mmHg, reaches a nadir after 30–60 min, and persists for
the duration of the procedure [8–10].The severity of hypox-
emia varies according to the type of dialysis membrane and
the chemical nature of the dialysate buffer [11,12]. Several
mechanisms have been proposed to explain the decrease in
arterial PO2: (1) a shift in the oxyhemoglobin dissociation
curve caused by the increase in pH during the procedure, (2)
depression of central respiratory output due to alkalosis, (3)
oxygen diffusion impairment, (4) ventilation–perfusion mis-
matching due to stasis of leukocytes in small pulmonary ves-
sels, and (5) hypoventilation due to carbon dioxide excretion
via the dialysate. Some changes found in patients with CKF
undergoing dialysis are also observed in transplant patients,
even after restoration of kidney function. These changes can
be partially attributed to immunosuppressive therapy, which
Y-NC-ND license.commonly uses corticosteroids. This medication is associated
with decreased synthesis and increased protein catabolism,
which could hamper full return of the functions of kidney
transplant patients [13].The aim of the work
The aim of this study was to evaluate pulmonary function
(including resting spirometry included ﬂow volume loop and
Maximal Voluntary Ventilation (MVV), measurement of lung
volumes and diffusing capacity for carbon monoxide), 6MWT
and ABG among patients with CRF undergoing hemodialysis
and patients with kidney transplant.Materials and methods
This study was conducted in King Fahd hospital in Almadinah
Al Monawarah, Kingdom Saudi Arabia from December 2011
to December 2012 on a cohort of 60 subjects. The study pro-
tocol was approved by the local ethics committee. Informed
consent was obtained from the patients. The subjects were
classiﬁed into 3 groups:
Group I: hemodialysis group (HDG): included 20 patients
with end stage renal disease (ESRD) on regular hemodialysis.
They included (7 men and 13 women). These individuals had
been undergoing hemodialysis regularly for at least six months.
They were clinically stable, without anemia, and were under
clinical follow-up. Group II: transplant group (TG): Included
20 patients (8 men and 12 women) who had undergone kidney
transplant at least six months earlier. These patients were sta-
ble from a clinical and surgical point of view and were also un-
der regular clinical follow-up. Group III: control group (CG):
included 20 apparently healthy subjects (9 men and 11 wo-
men). These were of the same age and gender as the other
two groups and fulﬁlled the same criteria for non-inclusion.
The exclusion criteria were history of respiratory diseases,
and cardiac insufﬁciency, being a smoker or ex-smoker, cur-
rent respiratory infections, musculoskeletal disorders, and
those who were unable to cooperate.
All subjects were subjected to:
1. Thorough history taking and full clinical examination.
2. Chest X-ray picture was taken before each study, and if it
was abnormal, the patient was eliminated from the study.
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hemodialysis for at least six months before the ﬁrst tests
were done. Pulmonary function, 6MWT and ABG studies
were carried out on the day after hemodialysis. The time
interval between the end of hemodialysis and the post-dial-
ysis study was 8–16 h. Blood transfusions were not given.
4. For transplant group (TG): the same studies were done at
least six months after renal transplantation at a time when
the function of the transplanted kidney was good as deﬁned
by a blood urea nitrogen level less than 40 mg percent or
creatinine clearances over 30 ml/min.
5. Also all subjects underwent pulmonary function testing;
including resting spirometry included ﬂow volume loop
and Maximal Voluntary Ventilation (MVV) [14], measure-
ment of lung volumes [15] and diffusing capacity for carbon
monoxide (DLCO) using the single breath technique [16]
which were performed using computerized equipment (V.
Max 225 Auto box) sensor medics system. Ambient temper-
ature and pressure were entered with the patient data (age
in years, weight in kilograms, height in centimeters and
sex). So that all results were calculated as percent of pre-
dicted except for FEV1/FVC%.
6. Six-Minute Walk Test [17]: the test was conducted between
10 a.m. and 4 p.m. for all subjects. A thirty-meter ﬂat,
obstacle-free corridor with a chair placed at either end
was used. Patients were instructed to walk as far as possible
to cover the longest possible distance over six minutes
under supervision. The patient was instructed that the
object of this test is to walk as far as possible for 6 min
through walking back and forth in this hallway. You are
permitted to slow down, to stop and to rest as necessary.
You may lean against the wall while resting, but resume
walking as soon as you can.
7. Arterial blood was analyzed for pH, PaO2 and PaCO2 with
an Instrumentation Laboratory blood gas analyzer,
RAPID Lab 248/348 Systems.
8. Patients were on regular hemodialysis 3 times/week, using
Fresenius 4008s, each session 4 h. Dry weight adjusted
according to clinical assessment each visit. Renal transplan-
tation was carried out according to standard procedures.
Transplanted patients had stable graft function with no his-
tory of rejection in the last 3 months, or admission for hos-
pital. All of them were on cyclosporine, mycophenil mofetil
and prednisolone.Table 1 Characteristics of the studied subjects.
Hemodialysis (HDG) (n= 20) Transplantat
Age (years) 42.40 ± 3.89 38.60 ± 4.51
Sex (M/F) 7/13 8/12
Smoking history Non Non
HB (gm/dl) 10.20 ± 0.77 11.95 ± 0.83
Albumin (g/L) 27.70 ± 3.40 29.85 ± 1.73
Urea (mmol/L) 12.05 ± 3.02 9.25 ± 2.27
Creatinine (lmol/L) 317.75 ± 84.77 118.55 ± 27.
Calcium (mmol/L) 2.185 ± 0.15 2.035 ± 0.18
Phosphorous (mmol/L) 0.945 ± 0.13 1.055 ± 0.23
ANOVA p< 0.01 between groups; post-hoc Fisher’s LSD (least signiﬁca
Age (years) (F= 3.079, p= 0.054). HB gm/dl (F= 48.524, p< 0.001; L
p< 0.001; LSD CG>HDG; CG> TG; TG>HDG). Urea (F=
(F= 116.013, p< 0.001; LSD CG<HDG; TG<HDG,). Calcium
CG<HDG; CG< TG).Statistical analysis
Statistical analysis was performed using MedCalc Software
Version 12.2.1 (MedCalc Software bvba. MedCalc Software,
Broekstraat 52, 9030 Mariakerke, Belgium). The results were
shown as means (and standard deviations). To compare the
groups in relation to parameters with normal distribution,
one-way ANOVA with post-hoc Fisher’s LSD (least signiﬁcant
difference) was used. To compare two independent samples we





The relationships between the lungs and the kidneys are clini-
cally important ones in both health and disease. Chronic renal
failure may affect respiratory function [18]. Pulmonary dys-
function may be the direct consequence of circulating uremic
toxins or may result indirectly from volume overload, anemia,
immune suppression, extra osseous calciﬁcation, malnutrition,
electrolyte disorders, and/or acid–base imbalances [4]. In our
study we found that there was a signiﬁcant difference between
HDG, TG and CG regarding FVC% of predicted (p< 0.001,
mean ± SD of HDG was 80.65 ± 3.51, TG was 82.55 ± 3.57
and for CG was 84.80 ± 2.14), FEV1% of predicted
(p= 0.001, mean ± SD of HDG was 80.45 ± 3.56, TG was
82.45 ± 2.74 and for CG was 84.25 ± 2.84), FEF 25–75%
of predicted (p< 0.001, mean ± SD of HDG was
74.40 ± 2.96, TG was 82.25 ± 4.41 and for CG was
84.30 ± 1.89), PEFR% of predicted (p< 0.001, mean ± SD
of HDG was 80.45 ± 4.12, TG was 84.05 ± 3.21 and for
CG was 87.75 ± 2.22) and MVV% of predicted (p< 0.001,
mean ± SD of HDG was 76.75 ± 4.08, TG was
81.15 ± 2.91 and for CG was 87.30 ± 2.41). Also there was
a statistically signiﬁcant difference between HDG, TG and
CG regarding RV% of predicted (p< 0.001, mean ± SD of
HDG was 118.50 ± 9.06, TG was 116.05 ± 8.42 and for CGion (TG) (n= 20) Control (CG) (n= 20) p-Value F Value
39.450 ± 6.48 p= 0.054 3.079
9/11
Non
13.20 ± 1.24 p< 0.001 48.524
34.45 ± 2.52 p< 0.001 34.085
10.25 ± 2.19 p= 0.003 6.332
23 88.55 ± 9.90 p< 0.001 116.013
1.721 ± 2.24 p= 0.518 0.665
0.80 ± 0.22 p< 0.001 8.81
nt difference).
SD CG>HDG; CG> TG; TG>HDG,). Albumin (F= 34.085,
6.332, p= 0.003; LSD CG<HDG; TG<HDG,). Creatinine
(F= 0.665, p= 0.518). Phosphorous (F= 8.81, p< 0.001; LSD
Table 2 Comparison between different studied groups as regards pulmonary function and 6MWT.
Hemodialysis (HDG) (n= 20) Transplantation (TG) (n= 20) Control (CG) (n= 20) p-Value F Value
FVC(%pred) 80.65 ± 3.5135 82.55 ± 3.5759 84.80 ± 2.142 p< 0.001 8.713
FEV1 (%pred) 80.45 ± 3.5600 82.45 ± 2.7429 84.25 ± 2.8447 p= 0.001 7.701
FEV1/FVC 81.35 ± 1.8144 82.60 ± 2.0622 82.10 ± 2.1981 p= 0.156 1.919
FEF 25–75 (%pred) 74.40 ± 2.9629 82.25 ± 4.4114 84.30 ± 1.8946 p< 0.001 51.474
PEFR (%pred) 80.45 ± 4.1228 84.05 ± 3.2196 87.75 ± 2.2213 p< 0.001 24.751
MVV (%pred) 76.75 ± 4.0766 81.15 ± 2.9069 87.30 ± 2.4083 p< 0.001 54.582
RV (%pred) 118.50 ± 9.06 116.05 ± 8.42 107.00 ± 4.94 p< 0.001 12.40
TLC (%pred) 88.70 ± 6.41 86.10 ± 4.70 83.75 ± 4.55 p= 0.017 4.38
RV/TLC (%pred) 133.72 ± 6.62 134.87 ± 8.05 127.93 ± 5.54 p= 0.004 5.96
DLco (%pred) 75.15 ± 14.3317 83.55 ± 4.1861 86.20 ± 1.8806 p< 0.001 8.818
DLco/AV (%pred) 70.70 ± 17.0390 84.30 ± 3.6288 86.45 ± 1.8489 p< 0.001 14.260
6MWT (meter) 395.20 ± 60.43 459.00 ± 68.17 535.55 ± 63.68 p< 0.001 24.436
ANOVA p< 0.01 between groups; post-hoc Fisher’s LSD (least signiﬁcant difference).
FVC (F= 8.713, p< 0.001; LSD CG>HDG; CG> TG). FEV1 (F= 7.701, p< 0.001; LSD CG>HDG; TG>HDG,). FEV1/FVC%
(F= 1.919, p< 0.156). FEF 25–75 (F= 51.474, p< 0.001; LSD CG>HDG, TG>HDG). PEFR (F= 24.751, p< 0.001; LSD
CG>HDG; CG> TG; TG>HDG). MVV (F= 54.582, p< 0.001; LSD CG>HDG; CG> TG; TG>HDG). RV (%pred) (F= 12.40,
p< 0.001; LSD CG<HDG; CG< TG). TLC (%pred) (F= 4.38, p= 0.017; LSD CG<HDG). RV/TLC% (F= 5.96, p= 0.004; LSD
CG<HDG; CG< TG). DLco (%pred) (F= 8.818, p< 0.001; LSD CG>HDG; TG>HDG). DLco/AV (%pred) (F= 14.260,
p< 0.001; LSD CG>HDG; TG>HDG). 6MWT (F= 24.436, p< 0.001; LSD CG>HDG; CG> TG; TG>HDG).
Table 3 Comparison between different studied groups as regards arterial blood gases (ABG):
Hemodialysis (HDG) (n= 20) Transplantation (TG) (n= 20) Control (CG) (n= 20) p-Value F Value
PH 7.37 ± 0.020 7.37 ± 0.022 7.38 ± 0.024 p= 0.311 1.191
Pao2 (mmHg) 80.45 ± 3.63 82.05 ± 1.93 85.65 ± 2.62 p< 0.001 17.872
Paco2 (mmHg) 38.55 ± 2.93 40.40 ± 3.65 39.75 ± 1.74 p= 0.12 2.121
Hco3 (mEq/L) 21.00 ± 1.17 19.90 ± 0.79 22.00 ± 1.49 p= 0.35 1.06
ANOVA p< 0.01 between groups; post-hoc Fisher’s LSD (least signiﬁcant difference).
PH (F= 1.191, p= 0.311). Pao2 (F= 17.872, p< 0.001; LSD CG>HDG; CG> TG: HDG> TG). Paco2 (F= 2.121, p= 0.12). Hco3
(F= 1.06, p= 0.35).
148 M.E. Abdalla et al.was 107.00 ± 4.94), TLC% of predicted (p= 0.017,
mean ± SD of HDG was 88.70 ± 6.41, TG was
86.10 ± 4.70 and for CG was 83.75 ± 4.55) and RV/TLC%
(p= 0.004, mean ± SD of HDG was 133.72 ± 6.62, TG
was 134.87 ± 8.05 and for CG was 127.93 ± 5.54). Although
FVC% of predicted and FEV1% of predicted were within the
normal range in the 3 studied groups, there was a statistically
signiﬁcant reduction in these spirometric parameters in HDG
more than that in the TG and CG, also reduction in TG more
than CG. These results are in agreement with those of Kovac-
evic et al. [19] who found that patients who are on long term
hemodialysis show a signiﬁcant decline in FVC. We found also
FEF 25–75% of predicted was less than normal in HDG and
was within the normal range in TG and CG this means that
there was a small airway obstruction in HDG, also RV% of
predicted and TLC% of predicted were increased in HDG
more than that in TG and CG. These spirometry ﬁndings sug-
gest that a small ‘airway disease cause increased RV and TLC
in HDG. These results are in agreement with those of Karacon
et al. [20] who found signiﬁcantly higher residual volume and
total lung capacity in the hemodialysis and peritoneal dialysis
groups than in the transplantation group. Forced expiratory
ﬂow between 25% and 75% of vital capacity was slightly be-low normal in the dialysis patients. Also Kalender et al. [21]
studied the effect of renal transplantation on pulmonary func-
tion and found that peak expiratory ﬂow (PEF 25–75) was de-
creased in the uremic group than that in the transplant group.
Another component in the spirometric evaluation was MVV%
of predicted, it was less than normal value in HDG and was
within normal values in TG and CG (but TG less than CG)
this means that HDG and TG have limitation to their ventila-
tor capacity. These results match with those of Zarday et al.
[22] and Guleria et al. [23] who concluded that the improve-
ment in MVV in the post transplant group was statistically sig-
niﬁcant and found that this increase, however, may reﬂect a
general improvement in the patients’ physical condition and
muscle strength, rather than any speciﬁc pulmonary improve-
ment. Also Bush and Gabriel [24] found that the MVV was
lower in the HDG and TG than in the CG, thus concluded that
patients with CKF undergoing dialysis and kidney transplant
patients have limitations to their ventilatory capacity. Wanic-
Kossowska [25] evaluated 18 patients on hemodialysis and
found a reduced maximal breathing capacity and an increased
residual volume among them.
Regarding diffusion capacity for carbon monoxide
(DLco% of predicted) we found signiﬁcant differences be-
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and CG (p< 0.001, mean ± SD of HDG was 75.15 ± 14.33,
TG was 83.55 ± 4.18 and for CG was 86.20 ± 1.88). Also we
found similar results regarding Diffusion per Unit of Alveolar
Volume (Dlco/VA% of predicted). HDG was less than TG
and CG (p< 0.001, mean ± SD of HDG was
70.70 ± 17.039, TG was 84.30 ± 3.63 and for CG was
86.45 ± 1.85) this was in accordance with Bush and Gabriel
[24] who concluded that abnormalities of lung function are
very common in renal failure, the major ﬁnding being a reduc-
tion in carbon monoxide transfer factor. They believed that the
likeliest cause of the low carbon monoxide transfer factor be-
fore transplantation is subclinical pulmonary edema or inter-
stitial ﬁbrosis secondary to recurrent pulmonary edema.
Pulmonary edema would be favored by increased vascular per-
meability, ﬂuid overload, and a low serum albumin concentra-
tion. Dujic et al. [26] found a reduction of TLCO in 25 patients
receiving hemodialysis, which was related to anemia given that
TLCO decrease reversed with blood transfusion. Zarday et al.
[22] found impairment of the diffusion capacity for carbon
monoxide in DG and this showed a slight improvement in
post-transplant period and explained this by the anemia
accompanying renal disease and not to azotemia itself. Herrero
et al. [27] concluded that in patients maintained on hemodial-
ysis for a long time, there is a selective impairment in pulmon-
ary diffusing capacity. Kalender et al. [21] found that there was
a slight decrease in the diffusion capacity in the uremic group
and normal diffusion capacity in the transplanted group.
In the present study we evaluated 6MWT among the stud-
ied groups and we found that there were statistically signiﬁcant
differences among the studied groups (p< 0.001, mean ± SD
of HDG was 395.20 ± 60.43, TG was 459.00 ± 68.17 and for
CG was 535.55 ± 63.68). These results are in agreement with
those of Oh-Park et al. [28] who evaluated the 6MWT and
found that the CKF patients walked distances that were short-
er than what is considered to be normal, with a mean of 405 m
for dialysis patients (a value slightly lower than what was
found in the present study). Cury et al. [29] studied the pul-
monary function and the functional capacity among patients
with CKF undergoing dialysis and among kidney transplant
patients and found that the 6MWT in their study demon-
strated that individuals in the HDG and TG had worse results
than did those in the CG. Our results were in disagreement
with Becker-Cohen et al. [30] who evaluated the 6MWT in
children and young adults with CKF and with kidney trans-
plants who were still undergoing dialysis and found values
within normality. Although there were no speciﬁc predictive
values for children, they found that on an average, the distance
that they were able to walk was only 100 m less than what the
adults who were evaluated could achieve. Those authors there-
fore considered this result to be normal.
Table 3 showed comparison between the different studied
groups as regards arterial blood gases (ABG). Although all
values were within normal levels, PaO2 in HDG was less than
that in TG and CG (p< 0.001, mean ± SD of HDG was
80.45 ± 3.63, TG was 82.05 ± 1.93 and for CG was
85.65 ± 2.62). Morales et al. [31] studied the lung function
pre- and post renal transplantation on 21 patients and deter-
mined spirometry including lung volumes, arterial blood gases,
DLCO and DLco/AV before and 3, 6, and 12 months after
transplantation. They concluded that spirometric and blood
gases data remained within reference levels during the followup. Ahluwalia et al. [32] studied pulmonary functions during
peritoneal dialysis and found no signiﬁcant differences in
PaO2, PaCO2 or PH during any phase of the study. Herrero
et al. [27] studied pulmonary diffusion capacity in chronic dial-
ysis patients and found that PaO2 and PaCO2 were similar in
all the groups with no signiﬁcant differences. PH and bicar-
bonate were within normal values in all groups although it is
less in group 1 without dialysis than in group 2 and 3 with
hemodialysis.Conclusions
According to our ﬁndings, it can be concluded that patients
with CRF undergoing hemodialysis and patients with kidney
transplantation show lower values regarding lung function
and 6MWT than those of the general population and that pa-
tients undergoing hemodialysis have greater impairment of
lung function and 6MWT than do kidney transplant patients.
Blood gas data remained within normal reference levels
although there was a signiﬁcant difference between the 3
groups regarding PaO2.References
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